(Q39360350)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526592%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

title

Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526592%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

May C I Van Schalkwyk

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526592%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Carol Box

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526592%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

John Maher

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526592%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Scott Wilkie

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526592%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Steve Hobbs

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526592%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

David M Davies

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526592%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Sjoukje J C van der Stegen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526592%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Ana C Parente Pereira

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526592%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Sophie E Burbridge

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526592%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Suzanne A Eccles

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526592%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

publication date

17 April 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526592%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Immunology

29 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526592%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526592%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526592%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

1059-1070

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526592%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10875-012-9689-9

29 January 2020

exact match

0 references

cites work

Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?".

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

Combining the antigen processing components TAP and Tapasin elicits enhanced tumor-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

Immunoediting sculpts tumor epitopes during immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

Regression of experimental medulloblastoma following transfer of HER2-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

Rat monoclonal antibodies to the external domain of the product of the C-erbB-2 proto-oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

Retroviral-mediated gene transfer in primary murine and human T-lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

Human breast cancer cell lines co-express neuronal, epithelial, and melanocytic differentiation markers in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

Efficient discrimination between different densities of target antigen by tetracycline-regulatable T bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

CAR mechanics: driving T cells into the MUC of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9689-9

Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen

21 January 2018

1 reference

12 December 2020

Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction

1 reference

12 December 2020

Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product

1 reference

12 December 2020

The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens

1 reference

12 December 2020

Complexity of expression of antigenic determinants, recognized by monoclonal antibodies HMFG-1 and HMFG-2, in normal and malignant human mammary epithelial cells

1 reference

12 December 2020

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience

1 reference

12 December 2020

Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes

1 reference

12 December 2020

T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis

1 reference

12 December 2020

Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events

1 reference

12 December 2020

Differences in the stimulating capacity of immobilized anti-CD3 monoclonal antibodies: variable dependence on interleukin-1 as a helper signal for T-cell activation

1 reference

12 December 2020

Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma

1 reference

12 December 2020

Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes.

1 reference

12 December 2020